Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Conjugated estrogens Clear all
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

NCT00234819
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • Fort Myers, Florida • North Port Richey, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Results available

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

NCT01070979
View directory record Official record
Conditions
Hormone Replacement Therapy
Interventions
Estradiol acetate, Estradiol, Conjugated equine estrogens
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
32
States / cities
Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)

NCT00973102
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Premarin IV, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Results available

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

NCT01958073
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Conjugated Estrogen Vaginal Cream, Estradiol Ring, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

NCT00224094
View directory record Official record
Conditions
Menopause
Interventions
Premarin® (oral) vs. Alora® (transdermal)
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
42 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

NCT00479778
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Not applicable Interventional Results available

Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy

NCT02691936
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause
Interventions
CO2 fractionated vaginal laser, Estrogens, Conjugated (USP)
Device · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Stanford, California • Washington D.C., District of Columbia • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

NCT00604825
View directory record Official record
Conditions
Menopausal and Female Climacteric States
Interventions
Other: Placebo, GSK232802, PREMARIN
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

NCT03740009
View directory record Official record
Conditions
Perimenopausal Disorder, Depression
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 2, 2026, 7:17 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

NCT04821141
View directory record Official record
Conditions
Risk Reduction, Breast Cancer
Interventions
Bazedoxifene and Conjugated Estrogens
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years to 64 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
6
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 2, 2026, 7:17 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz, Premarin, Placebo cream
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 100 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Results available

Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen

NCT02431897
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
Interventions
Conjugated Estrogens Cream, Placebo Cream
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
48 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 2, 2026, 7:17 PM EDT
Terminated Phase 3 Interventional

Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer

NCT00002976
View directory record Official record
Conditions
Endometrial Cancer
Interventions
conjugated estrogens
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
2,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
149
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

NCT02100553
View directory record Official record
Conditions
Healthy
Interventions
CE/BZA, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

NCT00474851
View directory record Official record
Conditions
Endometriosis
Interventions
Norethindrone acetate + estrogens, norethindrone acetate + placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 22 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2015 · Synced Sep 2, 2026, 7:17 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms

NCT04379024
View directory record Official record
Conditions
Focus of Study is Healthy Women at Risk for Breast Cancer
Interventions
DUAVEE 0.45Mg-20Mg Tablet
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 2, 2026, 7:17 PM EDT
Terminated No phase listed Observational

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

NCT00847821
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2010 · Synced Sep 2, 2026, 7:17 PM EDT
Terminated Phase 4 Interventional Results available

Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

NCT03018106
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Ospemifene, Vaginal conjugated estrogens
Drug
Lead sponsor
Emory University
Other
Eligibility
40 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

NCT00472927
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA 0.45 mg/1.5 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 2 Interventional

The PROMISE Study: Duavee in Women With DCIS

NCT02694809
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Postmenopausal
Interventions
Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Chicago, Illinois • Geneva, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 2, 2026, 7:17 PM EDT
Withdrawn Phase 2 Interventional

Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans

NCT05073237
View directory record Official record
Conditions
Menopause, Prediabetes, Obesity
Interventions
Placebo, conjugated estrogens/bazedoxifene (CE/BZA)
Other · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 2, 2026, 7:17 PM EDT
Terminated Phase 3 Interventional

Safety of Estrogens in Lupus: Hormone Replacement Therapy

NCT00000419
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Premarin and Provera
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 2, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Results available

Investigation of the Effect of the Female Urinary Microbiome on Incontinence

NCT02835846
View directory record Official record
Conditions
Overactive Bladder, Incontinence, Nocturia
Interventions
Estrogen Cream
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 2, 2026, 7:17 PM EDT
Terminated Not applicable Interventional

Study of PET Scans and Serotonin in Hot Flashes Treatment

NCT00249847
View directory record Official record
Conditions
Hot Flashes
Interventions
Paroxetine controlled-release, Conjugated equine estrogen
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 2, 2026, 7:17 PM EDT